Empo Health® Raises $7M to Launch a Category-leading System for Remote Diabetic Foot Ulcer (DFU) Management
New funding supports market launch of Empo's pioneering at-home monitoring system to help prevent diabetic amputations and reduce healthcare costs for high-risk patients.
SAN BRUNO, Calif., June 24, 2025 /PRNewswire/ -- Empo Health, Inc. today announced the commercialization of its innovative solution for diabetic foot ulcer (DFU) management, on the heels of its most recent $7 million fundraising round. The round was led by Story Ventures, with participation from VTC Ventures, alongside existing investors including Ulu Ventures, SeaX Ventures, Arben Ventures, and Gaingels. This funding brings Empo's capital raised to-date to $15 million.
Over 20 million Americans suffer from diabetic neuropathy and are at high risk of developing DFUs, which consume up to $80 billion in US healthcare spending annually. Without proper monitoring and care, DFUs can lead to costly disability, hospitalizations, and amputations. Most of these amputations are preventable with appropriate surveillance.
Physicians prescribe Empo's solution to patients with neuropathy who have lost protective sensation in their feet. The system combines the FDA-listed Empo® Footprint imaging scale with the HIPAA-compliant Empo® Remote Health Link patient monitoring service, enabling regular at-home monitoring of feet for early intervention by healthcare providers. A patient simply steps on the scale at home to generate an easily-understandable full-color visual image of their feet. The image is automatically transmitted to the care team, enabling early detection and appropriate follow-up on potential issues. In a pilot study, Empo demonstrated near-daily patient engagement and successfully helped detect early indications of ulcers in half of the patient participants.
"We believe that the patients most in need of health monitoring currently have the most difficult access to it. We founded Empo to change that, meeting patients where they are in their homes and giving clinicians actionable tools to significantly reduce the diabetic foot amputations that drive patient mortality and high healthcare costs. We're excited to bring our solution to patients, providers, and payors commercially," said Anuj Khandelwal, Co-Founder & CEO of Empo Health.
In conjunction with the financing, three new members joined Empo's Board of Directors: Brian Yormak (Managing Partner at Story Ventures), Steve Reale (Partner and CFO at Ulu Ventures), and Partha Ray (formerly director at Dexcom and Johnson & Johnson).
"Empo represents a critical change in the technology landscape," said Brian Yormak, Managing Partner of Story Ventures. "Connected hardware enables proprietary software informed by real-world data. Through Empo's Footprint connected scale, the company is improving outcomes and care for millions of people with diabetes at risk of foot ulcers and amputations. We're incredibly excited to support the company as they go to market."
Empo's solution stands apart through its ease-of-use for both patients and providers. "The Empo Footprint is designed from the ground up to be approachable and simple for the patient, taking only a few seconds for the entire interaction," said Eric Dahlseng, Co-Founder and Chief Product Officer of Empo Health, "Our Empo Remote Health Link service displays full-color visual images that providers already know how to interpret, shared at the right time so they can remotely determine an appropriate course of action."
SeaX Ventures is a global venture capital firm investing in deep-tech companies. "We're excited to invest in Empo because they're solving an important problem with empathy, precision, and purpose," said Dr. Kid Parchariyanon, Founder and Managing Partner at SeaX Ventures. "At SeaX, we exist to back mission-driven founders who are using science and technology to create real-world impact, especially in healthcare. Empo's work is a powerful example of that."
VTC Ventures is closely aligned with the strategic goals of Carilion Clinic, a not-for-profit, integrated, physician-led health system headquartered in Roanoke, Virginia, and its focus on patient-centered care and improving the health of the communities it serves. "We're thrilled to invest in Empo Health, an innovative company transforming healthcare with cutting-edge in-home monitoring solutions," said James Ramey, Managing Director of VTC Ventures. "Empo has been collaborating with Carilion, will continue to develop its technology here, and is soon initiating a study with our patients and providers."
With support from its investors and partners, Empo Health is focused on bringing its novel monitoring solutions to diabetic patients while demonstrating real value to providers, health systems and payors. For more information on Empo's newly launched solution, watch https://empohealth.com/#/video.
About Empo Health
Empo Health® is a healthcare technology company focused on improving patient outcomes with novel in-home health monitoring devices. The company has developed the FDA-listed Empo® Footprint and HIPAA-compliant Empo® Remote Health Link for monitoring diabetic foot complications. Empo was incorporated in 2020 by MIT-and-Stanford-trained technical founders, is based in the San Francisco Bay Area, and is supported by VC investors, angel investors, and SBIR grants. For more information, visit the company website and LinkedIn page.
About Story Ventures
Story Ventures is a New York City-based pre-seed and seed venture capital firm that invests in early-stage technology companies using data and information technologies to reshape how people interact with the world. Focused on the full data lifecycle—from creation to infrastructure to application—Story backs startups that generate, store, and analyze proprietary data to enable automation and machine intelligence.
Press Contact
SOURCE Empo Health
Share this article